December 26, 2019
Triplet Regimen Offers Improved Outcomes in BRAF-Mutant Colorectal Cancer BookmarkGeorge Lundberg, MD
Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
April 3, 2019
Emma Shtivelman, PhD
It has been over a year since I last wrote about new developments in treatment of melanoma, and it is time for an update. There is certainly some good news for melanoma patients! Neoadjuvant (before surgery) treatments for resectable melanoma Stage III—and more rarely, stage IV—melanoma tumors that have not spread widely can be sometimes treated surgically. Last year a small clinical trial showed… Read more »